“Bimekizumab Remission and High Disease Control Over 4 years in Patients with Psoriasis Achieving Complete Skin Clearance at Week 16: Results from Four Phase 3 Trials”, J of Skin, vol. 10, no. 2, p. s758, Mar. 2026, doi: 10.25251/0bnq3318.